Jeffrey Ecsedy

Company: Ikena Oncology

Job title: Chief Development Officer

Seminars:

Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape 9:00 am

What indications are showing most promise for therapeutic intervention on the Hippo pathway? Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs? How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’? What are the advantages/risks in targeting YAP/TAZ and…Read more

day: Conference Day One

TEAD Inhibition in Combination to Tackle Targeted Therapy Resistance in Oncology •Evaluating the context in which the Hippo pathway confers resistance to targeted therapies •Considering potential pathways and drugs to use in combination with TEAD inhibit 4:15 pm

Evaluating the context in which the Hippo pathway confers resistance to targeted therapies  Considering potential pathways and drugs to use in combination with TEAD inhibitors Exploring future steps at Ikena Read more

day: Conference Day One